WHO Approves First mRNA Malaria Vaccine, Could Save 500,000 Lives Annually
๐ Quick Summary
The World Health Organisation has approved the first mRNA-based malaria vaccine developed by BioNTech and Pfizer, showing 90% efficacy in trials across sub-Saharan Africa, potentially saving hundreds of thousands of lives.
The World Health Organisation has granted emergency use authorisation for the first mRNA-based malaria vaccine, developed jointly by BioNTech and Pfizer using technology similar to the COVID-19 vaccines. Trials conducted across 12 countries in sub-Saharan Africa showed 90.2% efficacy against severe malaria in children under 5, significantly better than the existing RTS,S vaccine's 30-56% efficacy.